Application of exosome-derived trimer store related immunological protein 59 inhibitor in regulating macrophage m2 polarization and resisting oral squamous cell carcinoma

By using exosomes derived from oral squamous cell carcinoma tissue to target TRIM59 and KRT6B inhibitors, combined with STING pathway agonists, highly efficient targeted delivery to tumor cells and immune microenvironment remodeling were achieved. This solved the problem of low TRIM59 inhibitor delivery efficiency in existing technologies and significantly inhibited tumor growth and invasion.

CN122321157APending Publication Date: 2026-07-03AFFILIATED HOSPITAL OF WEIFANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610630515.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-05-09
Publication Date
2026-07-03

Smart Images

  • Figure CN122321157A_ABST
    Figure CN122321157A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology and provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor uses exosomes derived from oral squamous cell carcinoma tissue as carriers, with the surface modified with the M2 macrophage-targeting molecule M2pep, internally loaded with TRIM59 inhibitors and KRT6B inhibitors, and loaded with STING pathway agonists. This invention relies on the microenvironment targeting and membrane surface targeting modification of tumor-derived exosomes to precisely deliver TRIM59 inhibitors and KRT6B inhibitors to M2 macrophages and tumor cells. By silencing TRIM59, the resistance of M2 macrophages to the STING pathway is relieved, forming a temporal synergistic effect of first unlocking and then activating with the STING agonist, driving macrophages to M1 polarization.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, and in particular relates to the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and in combating oral squamous cell carcinoma. Background Technology

[0002] Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the head and neck, accounting for more than 90% of oral cancers. Globally, the incidence and mortality rates of OSCC are increasing year by year, especially in less developed countries. Despite continuous advancements in traditional treatments such as surgical resection, radiotherapy, and chemotherapy, the 5-year survival rate for OSCC patients remains around 50%–60%, mainly due to early tumor invasion and metastasis, postoperative recurrence, and resistance to existing treatment regimens.

[0003] In recent years, tumor immunotherapy, especially strategies targeting the tumor microenvironment, has made groundbreaking progress. Tumor-associated macrophages (TAMs), as the most abundant immune cells in the tumor microenvironment, have phenotypes closely related to tumor prognosis. M2-type TAMs promote tumor immune escape, angiogenesis, and invasion and metastasis by secreting immunosuppressive factors such as IL-10 and TGF-β. Therefore, reprogramming M2-type TAMs into M1-type anti-tumor macrophages has become a cutting-edge direction in tumor immunotherapy.

[0004] TRIM59 (Tripartite Motif-containing Protein 59) is an E3 ubiquitin ligase that has been found to be highly expressed in various malignant tumors in recent years. It promotes tumor cell proliferation and the formation of an immunosuppressive microenvironment by activating signaling pathways such as STAT3 and NF-κB. Previous studies have shown that high expression of TRIM59 in macrophages can promote their M2 polarization, making it a key molecule in maintaining the immunosuppressive microenvironment. However, the development of inhibitors targeting TRIM59 is still in its early stages. Existing small-molecule inhibitors suffer from poor targeting and high off-target toxicity, and there is a lack of methods to specifically deliver TRIM59 inhibitors to tumor cells (TAMs).

[0005] On the other hand, keratin 6B (KRT6B), a member of the keratin family, has been found to be highly expressed in OSCC tissues in recent years and is closely related to poor patient prognosis. Previous studies have shown that KRT6B promotes the invasion and metastasis of OSCC cells by regulating epithelial-mesenchymal transition (EMT). However, there are currently no research reports on KRT6B as a therapeutic target, and no strategy of combined intervention with TRIM59 and KRT6B has been found.

[0006] Exosomes are cellularly secreted nanovesicles with a diameter of 30 nm to 150 nm, carrying various bioactive molecules such as proteins, mRNA, and miRNA, and serving as important mediators of intercellular communication. In recent years, exosomes have attracted widespread attention as drug delivery carriers due to their low immunogenicity, good biocompatibility, and natural targeting capabilities. However, existing exosome delivery systems are mostly derived from cell lines (such as HEK293 and RAW264.7), lacking homology characteristics with tumor tissues.

[0007] In summary, developing a tumor tissue-derived exosome delivery system that can simultaneously target TAMs M2 polarization and OSCC cell EMT, and achieve synergistic delivery of TRIM59 inhibitors and KRT6B inhibitors, is of great significance for improving the therapeutic effect of OSCC. Summary of the Invention

[0008] This invention provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma, thereby solving the technical problems of low delivery efficiency, lack of targeting, and inability to synergistically inhibit the malignant behavior of tumor cells in existing technologies.

[0009] This invention is achieved by using an exosome-derived TRIM59 inhibitor in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor is carried by exosomes derived from oral squamous cell carcinoma tissue. The surface of the exosomes is modified with M2 macrophage-targeting molecules, and the exosomes are loaded with both the TRIM59 inhibitor and the KRT6B inhibitor.

[0010] As a preferred embodiment of the present invention, the exosomes have an average particle size of 80-150 nm and are positive for exosome markers CD63 and TSG101, and negative for Calnexin.

[0011] In a preferred embodiment of the present invention, the M2 macrophage targeting molecule is M2pep, the amino acid sequence of which is shown in SEQ ID NO:1: SEQ ID NO: 1, YEQDPWGVKWWY.

[0012] This targeting molecule is inserted into the surface of the exosome membrane via the DSPE-PEG linker to achieve active targeting of M2 tumor-associated macrophages.

[0013] As a preferred embodiment of the present invention, the TRIM59 inhibitor is selected from at least one of TRIM59-specific siRNA, shRNA, and antisense oligonucleotides.

[0014] Preferably, the positive strand sequence of the TRIM59-specific siRNA is shown in SEQ ID NO:2, and is modified with 2'-O-methyl to improve its in vivo stability.

[0015] SEQ ID NO: 2,5'-GCAUCUACGUCAAGUUCAA-3'.

[0016] As a preferred embodiment of the present invention, the KRT6B inhibitor is selected from at least one of KRT6B-specific siRNA, shRNA, or antisense oligonucleotides.

[0017] Preferably, the positive strand sequence of the KRT6B-specific siRNA is as shown in SEQ ID NO:3, and is modified with 2'-O-methyl.

[0018] SEQ ID NO: 3,5'-CCUGGAGUUCGACAAGUAU-3'.

[0019] As a preferred embodiment of the present invention, the exosomes are further loaded with a STING pathway agonist, wherein the STING pathway agonist is selected from at least one of cGAMP, c-di-AMP or c-di-GMP.

[0020] The STING agonist and TRIM59 inhibitor form a pharmacokinetic synergistic effect of first unlocking and then activating: the TRIM59 inhibitor silences TRIM59 expression, relieves the resistance of M2 macrophages to the STING pathway, and then the STING agonist activates the STING-TBK1-IRF3 axis, driving macrophages to polarize towards M1.

[0021] The present invention also provides a method for preparing exosomes loaded with TRIM59 inhibitor and KRT6B inhibitor for use in the above-mentioned applications, comprising the following steps: (1) Exosome extraction: Cancer tissue of oral squamous cell carcinoma was taken, and primary tumor cells were extracted by enzymatic digestion. After culturing in a culture medium without exosome serum for 48 hours, the cell culture supernatant was collected, and exosomes were extracted by differential ultracentrifugation. (2) Drug loading: TRIM59 inhibitor and KRT6B inhibitor were co-loaded into the exosomes obtained in step (1) by electroporation. The electroporation parameters were 400 V voltage, 125 μF capacitance and 10 ms pulse time. After electroporation, RNase A was used to remove residual siRNA on the surface of the exosomes. When the exosomes were also loaded with STING pathway agonists, the agonists were loaded together. (3) Surface modification: M2 macrophage targeting molecules were modified onto the surface of the exosomes obtained in step (2) by hydrophobic insertion method. Specifically, DSPE-PEG2000-targeting molecules and exosomes were co-incubated at 37°C for 2 hours, and the exosomes were obtained after purification by ultracentrifugation. (4) Quality control: The obtained exosomes are tested for particle size, loading efficiency, sterility and cryopreservation stability to ensure that they meet pharmaceutical standards.

[0022] The present invention also provides the use of the above-mentioned exosomes in the preparation of drugs for treating oral squamous cell carcinoma.

[0023] Preferably, the drug exerts its antitumor effect by reversing M2 polarization of tumor-associated macrophages and inhibiting epithelial-mesenchymal transition in tumor cells.

[0024] More preferably, the drug works through the following mechanism: (1) The exosomes actively target M2 tumor-associated macrophages through surface-modified M2 macrophage targeting molecules, and silence TRIM59 expression by internally loaded TRIM59 inhibitors, thereby inhibiting the activation of the STAT6 signaling pathway and relieving the resistance of M2 macrophages to the activation of the STING pathway. (2) siTRIM59 silencing TRIM59 protein requires a certain time. After TRIM59 is fully silenced, the STING pathway agonist loaded in the exosome activates the STING-TBK1-IRF3 axis, promotes the release of type I interferon and pro-inflammatory factors, drives macrophages to M1 polarization, and forms a time-sequential synergistic effect in pharmacodynamics. (3) The exosomes simultaneously target oral squamous cell carcinoma cells, silence the expression of endogenous KRT6B in tumor cells by loading KRT6B inhibitors inside, upregulate E-cadherin, downregulate N-cadherin and Vimentin, and inhibit epithelial-mesenchymal transition. (4) M1 macrophages enhance CD8+ T cell infiltration and activation, and synergistically inhibit tumor growth.

[0025] Preferably, the drug is an injectable preparation, administered via intravenous injection, intratumoral injection, or local infiltration injection.

[0026] Compared with the prior art, the present invention has the following beneficial effects: This invention uses exosomes derived from oral squamous cell carcinoma tissue as delivery carriers. Tumor-derived exosomes have tumor microenvironment targeting capabilities, and their membrane surface protein profile makes them easier for cells in the tumor microenvironment to take up compared to exosomes derived from conventional cell lines. They also have higher biocompatibility and lower immunogenicity.

[0027] This invention combines the delivery of TRIM59 inhibitors and KRT6B inhibitors, overcoming the technical bottleneck of limited efficacy of single-target intervention. Through the exosome platform, it achieves a dual synergistic effect of immune microenvironment remodeling and tumor cell invasion inhibition. In vitro experiments showed that the M1 / M2 ratio increased to 6.90, and in vivo experiments showed a tumor inhibition rate of 78.0% and a median survival extended to 73 days, with significantly better results than single-target intervention.

[0028] This invention reveals that TRIM59 silencing can relieve the resistance of M2 macrophages to the STING pathway, and constructs a pharmacodynamic sequential synergistic system of first unlocking and then activating, thus solving the problem of weak responsiveness of M2 macrophages to STING agonists.

[0029] This invention achieves precise targeting of M2-type TAMs through M2pep modification, reducing off-target toxicity and systemic adverse reactions. No significant organ damage was observed in animal experiments. Attached Figure Description

[0030] Figure 1 This is a flowchart of the method for preparing exosomes provided by the present invention. Detailed Implementation

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs; the terminology used herein and in the specification of the application is for the purpose of describing particular embodiments only and is not intended to limit the invention; the terms "comprising" and "having," and any variations thereof, in the specification, claims, and foregoing drawings are intended to cover non-exclusive inclusion. The terms "first," "second," etc., in the specification, claims, or foregoing drawings are used to distinguish different objects and not to describe a particular order.

[0032] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of the invention. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a separate or alternative embodiment mutually exclusive with other embodiments. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0033] Example 1: Extraction and identification of exosomes from oral squamous cell carcinoma tissue 1.1 Organizational Origin Cancer tissue specimens were collected from 60 patients who underwent radical resection of oral squamous cell carcinoma in the Department of Oral and Maxillofacial Surgery at a tertiary hospital.

[0034] Inclusion criteria: (1) pathologically diagnosed oral squamous cell carcinoma; (2) undergoing radical surgery for oral squamous cell carcinoma; (3) aged 18-70 years; (4) complete clinical data.

[0035] Exclusion criteria: (1) coexisting malignant tumors; (2) severe heart, liver, kidney and nervous system diseases; (3) prior radiotherapy, chemotherapy or immunotherapy. This study was approved by the hospital ethics committee, and all patients signed informed consent forms.

[0036] 1.2 Primary tumor cell culture Take approximately 0.5–1.0 g of freshly removed cancerous tissue and place it in a sterile culture dish. Rinse the tissue three times repeatedly with PBS buffer containing 1% penicillin-streptomycin to remove blood and necrotic tissue. Cut the tissue into small pieces to approximately 1 mm in size. 3 The cells were sized and digested with 0.1% type IV collagenase and 0.01% DNase I at 37°C for 1 hour, with shaking every 15 minutes. After digestion, the cells were filtered through a 70 μm cell sieve, and the filtrate was collected. The cells were centrifuged at 300 g for 5 minutes, and the supernatant was discarded. The cell pellet was resuspended in DMEM / F12 medium (containing 10% exosome-free fetal bovine serum) and seeded into T25 culture flasks. The flasks were then incubated at 37°C in a 5% CO2 incubator. After 48 hours, the cell culture supernatant was collected for exosome extraction.

[0037] 1.3 Exosome Extraction Exosomes were extracted using differential ultracentrifugation. The specific steps are as follows: Centrifuge at 300 g for 10 minutes at 4°C to remove cell debris; Centrifuge at 2000 g for 20 minutes at 4°C to remove dead cells and large vesicles; Centrifuge at 10000 g for 30 minutes at 4°C to remove microvesicles; Centrifuge at 100,000 g, 4°C for 70 minutes, discard the supernatant, and resuspend the precipitate in PBS. Centrifuge again at 100,000 g, 4°C for 70 minutes. The precipitate is the exosome. Resuspend in an appropriate amount of PBS, aliquot, and store at -80°C for later use.

[0038] 1.4 Exosome Identification Transmission electron microscopy revealed that the extracted exosomes exhibited a typical cup-shaped morphology with a diameter ranging from 80 to 150 nm.

[0039] Dynamic light scattering particle size analysis showed that the average particle size of the exosomes was 112.3 ± 8.6 nm and the polydispersity index (PDI) was 0.18 ± 0.05.

[0040] Western blot analysis showed that the exosome sample was positive for CD63 and TSG101, while negative for the endoplasmic reticulum marker Calnexin, indicating that the extract was purified exosomes and was not contaminated by cell debris.

[0041] qPCR results showed that the expression level of KRT6B mRNA in OSCC tissue-derived exosomes was significantly higher than that in adjacent normal tissue-derived exosomes (P < 0.01), with an average expression level approximately 4.7-fold higher (see Table 1).

[0042] Table 1. Relative expression levels of KRT6B mRNA in exosomes

[0043] Example 2 Preparation of exosomes 2.1 Loading of siRNA and cGAMP Take 200 μg of exosomes, add 20 μg of siTRIM59 (sequence: 5'-GCAUCUACGUCAAGUUCAA-3', sense chain, modified with 2'-O-methyl), 20 μg of siKRT6B (sequence: 5'-CCUGGAGUUCGACAAGUAU-3', sense chain, modified with 2'-O-methyl), and 10 μg of cGAMP (MedChemExpress, HY-100922), and suspend in 400 μL of electroporation buffer (20 mM HEPES, 5 mM KCl, 0.5 mM MgCl2, 1 mM Na2HPO4, pH 7.2); transfer to a 4 mm electroporation cuvette, and use the Gene Pulser Xcell electroporation system with the following parameters: 400 V, 125 μF, 10 ms, single pulse; after electroporation, recover at 37°C for 30 minutes, and add RNase A (10 Incubate at 37°C for 30 minutes with RNase A (μg / mL), then centrifuge at 100,000 g, 4°C, for 70 minutes to remove free drug. Resuspend the precipitate in PBS. Since the exosome membrane has recovered its integrity after electroporation (37°C for 30 minutes), RNase A cannot enter the exosome interior. It only degrades the residual siRNA adsorbed on the surface and does not affect the loaded internal siRNA. Gel electrophoresis confirmed that the siRNA inside the exosome was intact after RNase A treatment.

[0044] 2.2 Surface M2pep modification DSPE-PEG2000-M2pep (M2pep sequence: YEQDPWGVKWWY) was dissolved in sterile PBS to prepare a 1 mg / mL working solution. The loaded exosomes were mixed with the working solution at a ratio of DSPE-PEG2000-M2pep to exosome protein of 1:4, resulting in a final M2pep concentration of 50 μg / mL. The mixture was incubated at 37°C with shaking for 2 hours. Unbound peptide-lipid complexes were removed by ultracentrifugation (100,000 g, 4°C, 60 min). The precipitate was resuspended in sterile PBS to obtain exosomes.

[0045] 2.3 Quality Control The exosomes had an average particle size of 115.6 ± 9.2 nm and a zeta potential of -18.3 ± 2.1 mV, indicating good dispersibility and no aggregation, meeting the requirements for injectable formulations. The loading efficiency of siTRIM59 was 59.0%, siKRT6B was 44.5%, and cGAMP was 82.0%. The exosomes were sterile and had an endotoxin content of <0.5 EU / mL, meeting the requirements for injection. The exosomes showed good stability after being frozen at -80℃ for 6 months.

[0046] 2.4 M2pep Surface Modification Efficiency Detection Flow cytometry was used to detect the fluorescence positivity rate of exosomes (Exo-M2pep / siT+K) and unmodified exosomes (Exo-siT+K). 100 μg of each was taken and incubated with FITC-labeled anti-M2pep antibody (1:100 dilution) at 4°C in the dark for 30 minutes. After washing to remove unbound antibodies by ultracentrifugation (100000g, 4°C, 60 minutes), the precipitate was resuspended in PBS and the fluorescence positivity rate of the exosome surface was detected by flow cytometry.

[0047] The results showed that the positive rate of unmodified exosomes was 3.2±0.8%, and the positive rate of exosomes was 86.5±4.2% (P<0.001), indicating that M2pep had been successfully modified on the surface of exosomes.

[0048] Example 3: Effects of exosomes on M2 macrophage polarization 3.1 Cell Culture and M2 Induction Human mononuclear cell line THP-1 was cultured in RPMI 1640 medium containing 10% fetal bovine serum. THP-1 cells were treated with 100 ng / mL PMA for 48 hours to induce differentiation into M0 macrophages; subsequently, they were treated with 20 ng / mL IL-4 and 20 ng / mL IL-13 for 48 hours to induce differentiation into M2 macrophages.

[0049] 3.2 Experimental Grouping M2 macrophages were seeded in 6-well plates (2 × 10⁻⁶ cells / well). 5(cells / pores), divided into: (1) PBS control group; (2) Unmodified exosome group (Exo-NC); (3) Exosomes loaded with siTRIM59 (Exo-siT); (4) Exosomes loaded with siKRT6B (Exo-siK); (5) The exosomes loaded with siTRIM59+siKRT6B (Exo-siT+K); (6) M2pep modified + co-loaded siTRIM59+siKRT6B exosome group (Exo-M2pep / siT+K, the present invention group); (7) The exosomes loaded with siTRIM59+siKRT6B+cGAMP (Exo-siT+K+G) were loaded together. (8) M2pep modified + co-loaded siTRIM59+siKRT6B+cGAMP exosome group (Exo-M2pep / siT+K+G, preferred group of the present invention).

[0050] The exosomes in each group were added at a dose of 50 μg protein per well, and cells were collected for detection after 48 hours of treatment.

[0051] 3.3 Flow cytometry detection of macrophage phenotype The proportions of M1 (CD86+) and M2 (CD206+) macrophages and the M1 / M2 ratio after treatment in each group are shown in Table 2.

[0052] Table 2. Macrophage phenotype detection results for each group (mean ± SD, n=3)

[0053] 3.4 qPCR detection of polarization-related factor mRNA expression qPCR results showed that the expression of M1-related factors (IL-12, TNF-α, iNOS) mRNA was significantly increased in the preferred group of this invention, while the expression of M2-related factors (IL-10, Arg-1, CD206) mRNA was significantly decreased (P<0.001) (see Table 3).

[0054] Table 3. Relative expression levels of polarization-related factor mRNAs (mean ± SD, n=3)

[0055] 3.5 Western blot detection of TRIM59 and STAT6 phosphorylation levels Western blot results showed that the expression level of TRIM59 protein in the present invention group (Exo-M2pep / siT+K) was reduced by 81.5±5.3% compared with the control group, and the p-STAT6 / STAT6 ratio was reduced by 76.8±4.6%, indicating that exosomes effectively silenced TRIM59 expression and inhibited the activation of the STAT6 signaling pathway.

[0056] 3.6 Effects of TRIM59 silencing on STING pathway responsiveness To verify the effect of TRIM59 silencing on the STING pathway response, free siTRIM59 (transfected with cationic liposome transfection reagent) with the same sequence as exosomes was used for pretreatment to simulate the gene silencing effect after exosome delivery. The following groups were set up: (1) M2 macrophages + cGAMP; (2) M2 macrophages + siTRIM59 pretreatment for 24h + cGAMP; (3) M2 macrophages + siTRIM59 + cGAMP treatment simultaneously.

[0057] The levels of p-TBK1 protein and IFN-β mRNA were detected, and the results are shown in Table 4.

[0058] Table 4. Effect of TRIM59 silencing on STING pathway responsiveness (mean ± SD, n=3)

[0059] The results showed that TRIM59 silencing could restore the sensitivity of M2 macrophages to STING agonists, achieving temporal synergy.

[0060] 3.7 Dynamic verification of the time-series synergistic effect of co-loaded exosomes To directly verify whether the co-loaded exosomes of the present invention achieve temporal synergy of unlocking first and then activating under simultaneous delivery conditions, the following two groups were set up: (1) Exo-M2pep / siT+K+G (co-loaded group, containing siTRIM59, siKRT6B and cGAMP); (2) Exo-M2pep / siT+G (cGAMP control group only, without siTRIM59 and siKRT6B); M2 macrophages (50 μg protein / well) were added respectively, and cells were collected at 0h, 4h, 8h, 12h, 24h and 48h. The TRIM59 protein level, p-TBK1 / TBK1 ratio and IFN-β mRNA expression were detected. The results are shown in Table 5.

[0061] Table 5. Time-series dynamic detection results of M2 macrophages after co-loading exosome treatment (mean ± SD, n=3)

[0062] In the cGAMP control group, p-TBK1 and IFN-β showed no significant changes at any time point, while in the co-loading group, they increased significantly from 12 to 24 h. Furthermore, the decrease in TRIM59 protein (8-12 h) occurred earlier than the activation of the STING pathway (12-24 h). These results indicate that delayed activation is not an inherent kinetic of cGAMP, but rather depends on TRIM59 silencing, thus verifying the temporal synergistic mechanism of unlocking followed by activation in the co-loading system.

[0063] Example 4: Effects of exosomes on EMT in OSCC cells Oral squamous cell carcinoma cell line SCC-15 was cultured in DMEM / F12 medium. Grouping and treatment were the same as in Example 3.2. Each group received 50 μg of protein per well for exosomes, and the samples were analyzed after 48 hours of treatment.

[0064] 4.1 Western blot detection of EMT-related biomarkers Western blot results showed that E-cadherin expression was significantly increased in the present invention group (Exo-M2pep / siT+K) and the preferred group (Exo-M2pep / siT+K+G), while N-cadherin, Vimentin, and Snail expression were significantly decreased (see Table 6). Western blot verification showed that KRT6B protein level was significantly decreased and had no tumor-promoting effect.

[0065] Table 6. Relative expression levels of EMT-related biomarkers (mean ± SD, n=3)

[0066] 4.2 Transwell Invasion Experiment The Transwell invasion assay results showed that the invasive ability of cells in the present invention group and the preferred group was significantly reduced (see Table 7).

[0067] Table 7 Results of Transwell invasion assay (number of invaded cells / field of view, mean ± SD, n=3)

[0068] 4.3 Scratch Healing Test The scratch healing experiment results showed that the cell migration ability of the present invention group and the preferred group was significantly reduced (see Table 8).

[0069] Table 8 Results of scratch healing experiment (24h healing rate, mean ± SD, n=3)

[0070] Example 5: In vivo antitumor pharmacodynamic evaluation 5.1 Animal Model Female NPG mice aged 6-8 weeks were used to reconstruct the human immune system using PBMCs and were subcutaneously inoculated with OSCC-PDX tissue. They were randomly divided into 6 groups (n=8): (1) PBS; (2) Exo-NC; (3) Exo-siT; (4) Exo-siT+K; (5) Exo-M2pep / siT+K; (6) Exo-M2pep / siT+K+G.

[0071] Dosing regimen Mice in all groups were administered the drug via tail vein injection, with each injection containing 200 μg of exosome protein, once every 3 days for a total of 6 administrations; the PBS group and the Exo-NC group were given an equal volume of solvent as a control.

[0072] Explanation of the model's rationality: M2pep can simultaneously bind to human and mouse M2 macrophages (Scodeller et al. Sci Rep. 2017;7:43241). This model is a general model for tumor immunotherapy, and the experimental results can reasonably reflect the targeting effect of the formulation.

[0073] It is known in the art that the M2 macrophage surface markers (such as CD206 and MR) recognized by M2pep are highly conserved between humans and mice, therefore this model can reasonably reflect the targeting effect.

[0074] 5.2 Efficacy Results Table 9 shows the changes in tumor volume, endpoint tumor weight, and median survival for each group.

[0075] Table 9. Antitumor efficacy results for each group (mean ± SD, n=8)

[0076] 5.3 Safety Evaluation There were no significant differences in body weight changes among the groups of mice. Mice were sacrificed at the experimental endpoint, and their hearts, livers, spleens, lungs, and kidneys were collected for H&E staining; no obvious pathological damage was observed. Serum ALT, AST, Cr, and BUN levels showed no significant differences among the groups (P > 0.05). This indicates that the exosomes of this invention have good biocompatibility.

[0077] Example 6 Regulation of the Tumor Immune Microenvironment Mice were sacrificed at the end of the experiment, and tumor tissue was used to prepare single-cell suspensions. Flow cytometry was used to detect the infiltration of immune cells in the tumor. The results are shown in Table 10.

[0078] Table 10. Proportion of intratumoral immune cell infiltration (mean ± SD, n=8)

[0079] Immunohistochemical analysis showed that the number of CD8+ T cells infiltrating and the proportion of Granzyme B positive cells in the present invention group and the preferred group were significantly higher than those in the control group.

[0080] The above results indicate that the exosomes of this invention significantly enhance the infiltration and activation of CD8+ T cells and reshape the tumor immune microenvironment by reversing the polarization of M2-type TAMs to M1-type.

[0081] The exosome preparation process of this invention is stable and controllable, with clear quality standards. The exosomes exhibit good cryopreservation stability, and the extract from a single surgical tissue can meet the needs of the entire course of treatment. Referring to the personalized cell exosome preparation specifications, it has the potential for reproducibility and large-scale production and can be used to prepare drugs for the treatment of oral squamous cell carcinoma.

[0082] It should be noted that, for the sake of simplicity, the foregoing embodiments are all described as a series of actions. However, those skilled in the art should understand that the present invention is not limited to the described order of actions, as some steps may be performed in other orders or simultaneously according to the present invention. Furthermore, those skilled in the art should also understand that the embodiments described in the specification are preferred embodiments, and the actions and modules involved are not necessarily essential to the present invention.

[0083] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit the scope of protection of the invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on these embodiments, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art can still combine, add, delete, or otherwise adjust the features of the various embodiments of the present invention according to the circumstances without conflict or creative effort, thereby obtaining different technical solutions that do not fundamentally depart from the concept of the present invention. These technical solutions also fall within the scope of protection of the present invention.

Claims

1. The application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and in combating oral squamous cell carcinoma, characterized in that, The TRIM59 inhibitor is carried by exosomes derived from oral squamous cell carcinoma tissue. The surface of the exosomes is modified with M2 macrophage-targeting molecules, and the exosomes are loaded with TRIM59 inhibitors and KRT6B inhibitors.

2. The application as described in claim 1, characterized in that, The exosomes had an average particle size of 80-150 nm and were positive for exosome markers CD63 and TSG101, but negative for Calnexin.

3. The application as described in claim 1, characterized in that, The M2 macrophage targeting molecule is M2pep, and its amino acid sequence is shown in SEQ ID NO:

1.

4. The application as described in claim 1, characterized in that, The TRIM59 inhibitor is selected from at least one of TRIM59-specific siRNA, shRNA, and antisense oligonucleotides.

5. The application as described in claim 4, characterized in that, The positive strand sequence of the TRIM59-specific siRNA is shown in SEQ ID NO:2 and is modified with 2'-O-methyl.

6. The application as described in claim 1, characterized in that, The KRT6B inhibitor is selected from at least one of KRT6B-specific siRNA, shRNA, or antisense oligonucleotide.

7. The application as described in claim 6, characterized in that, The positive strand sequence of the KRT6B-specific siRNA is shown in SEQ ID NO:3 and is modified with 2'-O-methyl.

8. The application as described in claim 1, characterized in that, The exosomes are also loaded with a STING pathway agonist, which is selected from at least one of cGAMP, c-di-AMP, or c-di-GMP.

9. A method for preparing exosomes loaded with TRIM59 inhibitor and KRT6B inhibitor for use in any one of the applications described in claims 1-8, characterized in that, Includes the following steps: (1) Take oral squamous cell carcinoma tissue, extract primary tumor cells, culture them and collect the supernatant, and extract exosomes by differential ultracentrifugation; (2) The TRIM59 inhibitor and the KRT6B inhibitor were co-loaded into the exosomes obtained in step (1) by electroporation. When the exosomes were also loaded with a STING pathway agonist, the agonist was loaded together. (3) Modify the surface of the exosomes obtained in step (2) with M2 macrophage targeting molecules by hydrophobic insertion method.

10. The preparation method according to claim 9, characterized in that, The electroporation parameters were 400 V voltage, 125 μF capacitance, and 10 ms pulse time. After electroporation, RNase A was used to remove residual siRNA on the surface. The hydrophobic insertion method involved co-incubating the DSPE-PEG2000-targeting molecule with exosomes at 37°C for 2 hours.